The pharma industry can find common ground on one thing: the cell and gene therapy (CGT) space right now is both incredibly exciting and daunting. Treatments that once seemed like science fiction are now becoming reality, transforming medicine in ways we never thought possible. However, with this rapid innovation comes equally significant challenges. While new breakthroughs are on the horizon, investment is volatile, and the stakes couldn’t be higher for manufacturers.
It’s not just about getting approvals—it’s about ensuring treatment centers are ready, pricing models are optimized, and operations can scale smoothly. Any misstep could mean delays for patients waiting on life-changing therapies.
At the recent Meeting on the Mesa, over 140 professionals gathered to hear “The Anatomy of a CGT Launch: Operationalizing Cell and Gene Therapy,” led by Kyle Felmet, Two Labs’s VP of Specialty Pharmacy. Industry leaders Austin Fisher (Autolus Therapeutics), Michael Storey (Nationwide Children’s Hospital), and Monet Stanford (Alliance for Regenerative Medicine) joined the panel and shared what it takes to successfully launch CGTs and ensure they reach the patients who need them most.
Early Commercial Planning: Timing is Everything
Q: How early should manufacturers begin thinking about commercial planning, and what are the first things they should focus on?
For CGT products, initiating commercial planning 18 to 24 months before launch is essential to setting up a smooth and successful entry into the market. Starting early ensures that the therapy is not only aligned with patient needs but also well-suited to the capabilities of treatment centers. Product configuration plays a significant role, impacting everything from supply chain logistics to how easily treatment centers can integrate the therapy. Key factors such as treatment center qualifications and clinical trial outcomes, which influence labeling and packaging, need to be considered upfront. By planning in advance, manufacturers will be able to build a distribution model that meets CGT-specific requirements, like ultra-cold storage and specialized logistics. Moreover, early preparation ensures a seamless transition from clinical trials to commercial operations, minimizing disruptions and avoiding costly last-minute adjustments.
Navigating the Complex Reimbursement Landscape
Q: What are the critical policy considerations and hurdles in ensuring patient access to CGTs, particularly regarding reimbursement?
Navigating CGT reimbursement requires understanding the complexities of Medicare, Medicaid, and various payer systems. Early engagement with policymakers and industry groups is critical to shaping reimbursement policies that work for patient access, particularly in cases involving multiple payers or rare diseases. As reimbursement models continue to evolve, manufacturers need to stay flexible, adapting to different policies for both inpatient and outpatient settings. There’s growing interest in outcomes-based pricing models, but these require collaboration to ensure that outcomes data is tracked and reported accurately. Building strategic partnerships can help manufacturers navigate these challenges and ensure patients have timely access to life-changing therapies.
Treatment Center Readiness: Key Success Factors
Q: How should manufacturers approach treatment centers to ensure a successful launch?
- Effective engagement with treatment centers is essential for the successful launch of CGT therapies. Early engagement with key stakeholders, especially within pharmacy, finance, and procurement, helps streamline the process and sets the stage for smoother commercialization.
- Understanding each center’s operational capabilities and aligning the manufacturer’s therapy introduction with their workflows is essential for avoiding bottlenecks.
- Since CGT therapies often require cross-departmental coordination, having clear points of contact—like clinical and financial champions—can help prevent delays.
- Centers of excellence are also being developed to standardize processes across research and commercial teams, optimizing efficiency and scalability.
Shifting Market Dynamics: From Ultra-Rare to Broader Indications
Q: As the CGT market shifts from ultra-rare to broader patient populations, what commercialization strategies should be considered?
The CGT landscape is expanding to treat more common conditions like sickle cell disease and autoimmune disorders. Manufacturers will need to adapt their commercialization strategies to meet new operational demands. Treatment centers will need to scale and standardize their processes to manage higher patient volumes, which could include shifting some therapies from inpatient to outpatient settings.
For manufacturers, understanding the infrastructure and capacity of treatment centers becomes increasingly important as they transition from handling rare, specialized treatments to handling more mainstream indications. Greater standardization, particularly in centers handling and managing multiple therapies, will be key to managing this shift effectively.
Supply Chain Challenges: Scaling Up CGT Distribution
Q: What unique distribution challenges do CGT therapies present compared to traditional drugs?
Scaling CGT distribution poses challenges due to the need for ultra-cold storage, multiple National Drug Codes (NDCs), and strict regulatory requirements. Early planning is essential for building flexible supply chains that can support both inpatient and outpatient settings. Establishing reliable logistics networks and ensuring treatment centers have the infrastructure to manage the specific demands of cell-engineered products are key to overcoming these hurdles, as CGT distribution requires a different approach than conventional pharmaceuticals.